Oncology/Hematology
News, opinions and meeting coverage in oncology/hematology.
— At 5 years, median PSA was reduced by 90%
Latest in Oncology/Hematology
Patients with treatment-sensitive disease may benefit most from continued treatment, says expert
Be aware of the potential for secondary malignancy in relation to LCH diagnosis, researchers urge
40% of patients treated with imetelstat were transfusion-free for at least 8 weeks
Phillip Pierorazio, MD, outlines how to be a good steward of active surveillance
40% of patients treated with imetelstat were transfusion-free for at least 8 weeks
Phillip Pierorazio, MD, outlines how to be a good steward of active surveillance
Oncology/Hematology Case Studies
Be aware of the potential for secondary malignancy in relation to LCH diagnosis, researchers urge
Man with a first-degree relative with CRC initially only agreed to stool-based testing
The cause lies in a lengthy history of cancer treatment, confirmed by histopathology analysis
More in Oncology/Hematology
A quarter patients with high-risk, BCG-unresponsive disease were recurrence free at 3 years
Response rates with pirtobrutinib reached 72% in heavily pretreated patient population
News, features, and commentary about cancer-related issues
Results from interim analysis suggest "potential to disrupt the NMIBC treatment landscape"
Keeping those mammogram appointments is life-saving, study finds
Investigational intravesical solution led to complete response rate of 79%
And our roundtable of experts discuss selinexor for wild-type p53 disease
Algorithm proved accurate where traditional risk models have failed, but needs more testing
Tool could identify nonsmokers most likely to benefit from low-dose CT screening
Applies to all approved therapies, but benefits still outweigh risks, agency says
The strategy was effective for patients who were due or overdue for screening
Nirogacestat reduced the risk of disease progression or death by 71% in randomized trial
